Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927563 · ClinicalTrials.gov registry record · Phase 2
Tolcapone Treatment of Pathological Gambling
A Phase 2 study of Pathological Gambling, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00927563: Completed Phase 2 study of Pathological Gambling, sponsored by University of Chicago.
NCT00927563 is a Phase 2 study of Pathological Gambling that has completed, run by University of Chicago. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00927563, a Phase 2 study of Pathological Gambling, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the proposed study is to evaluate the efficacy and safety of tolcapone in pathological gambling.
Primary Outcome
The overall impression of the clinician of the severity of the subject. Scores between 1 and 7 with 1 not being ill at all and 7 being one of the worst cases seen. CGI is assessed at every visit (1-5), but only the final visit will be reported here.
Conditions Studied
Interventions
- DRUG Tolcapone
Study Locations (1)
Minnesota
- Ambulatory Research Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT00927563 record still lists
NCT00927563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Pathological Gambling appearing as the primary indexed condition, and to 1 intervention - of which Tolcapone is the first listed.
NCT00927563 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00927563 about?
NCT00927563 is a clinical study titled "Tolcapone Treatment of Pathological Gambling". The goal of the proposed study is to evaluate the efficacy and safety of tolcapone in pathological gambling.
What is the current status of trial NCT00927563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-06. Estimated completion is 2012-07.
What conditions does trial NCT00927563 study?
This clinical trial studies the following conditions: Pathological Gambling.
What interventions are being tested in trial NCT00927563?
The interventions under investigation include: Tolcapone (DRUG).
Who is sponsoring clinical trial NCT00927563?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927563 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pathological Gambling
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00927563's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia